Send to

Choose Destination
J Invasive Cardiol. 2002 Jul;14(7):423-5.

Bleeding complications of platelet glycoprotein IIb/IIIa inhibitor abciximab (ReoPro ).

Author information

Division of Cardiology, Maimonides Medical Center, Brooklyn, NY 11219, USA.


Studies of patients scheduled for percutaneous coronary intervention with acute coronary syndrome have shown that the addition of intravenous glycoprotein (GP) IIb/IIIa inhibitors to aspirin and heparin is associated with a reduction in death or myocardial infarction compared to therapy with aspirin and heparin alone. The principle safety issue with GP IIb/IIIa inhibitors is the risk of bleeding, as the potent antiplatelet effect of these drugs may adversely affect hemostasis. In addition, antagonists of GP IIb/IIIa may increase the risk of thrombocytopenia. We report a case of abciximab-induced severe thrombocytopenia which led to fatal intra-cranial hemorrhage.

[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center